Mechanism of action and pharmacology of Pegcetacoplan-Empaveli

Pegcetacoplan (Pegcetacoplan), as a complement C3 targeted modulator, is currently one of the most advanced innovative therapies among complement system drugs in the world. It can directly bind to the complement protein C3 and its activation fragment C3b . By inhibiting the cleavage of C3 , the downstream complement cascade reaction can be systematically controlled, thereby alleviating a series of diseases with complement dysregulation as the core pathological mechanism. In paroxysmal nocturnal hemoglobinuria (PNH), red blood cells are susceptible to hemolysis due to complement attack, with C3b causing extravascular hemolysis (EVH) and the membrane attack complex (MAC) causing intravascular hemolysis (IVH).

Traditional drugs mostly target terminal complement (such as C5), but they cannot completely solve the extravascular hemolysis mediated by C3b, so some patients still have residual hemolysis problems. Because Pegcetacoplan targets the more upstream C3, it can simultaneously control EVH and IVH to achieve a more comprehensive anti-hemolytic effect. This is one of the important reasons why it has attracted much attention overseas in recent years. In C3G (C3 glomerulopathy) and IC-MPGN (primary immune complex membranoproliferative glomerulonephritis), overactivation of complement in the glomerulus leads to the deposition of C3 fragments, damaging the glomerular structure and gradually affecting renal function.

Pegcetacoplan intervenes in disease progression by inhibiting C3 activation and reducing C3 deposition in glomeruli. Its effects also include reducing the activity of C5 converting enzyme and reducing the production of C5b-9 terminal complex, thereby further reducing inflammation and immune damage. Pharmacologically, Pegcetacoplan is a subcutaneous administration preparation that can maintain stable blood concentration and avoid fluctuations in efficacy due to short half-life. Because it targets the upstream of the complement cascade, it has a wider range of theoretical applications and is therefore being used in the research fields of multiple complement-related diseases, including autoimmune diseases, rare blood diseases, and renal immune diseases.

As a new type of C3 inhibitor, its mechanistic advantage is mainly reflected in its ability to comprehensively balance complement functions and complement traditional terminal complement inhibitors. It is a representative of the changes in the development trend of complement drugs.

References: https://empaveli.com/